[go: up one dir, main page]

Greenberg et al., 1986 - Google Patents

The effect of calcium ions on the activated partial thromboplastin time of heparinized plasma

Greenberg et al., 1986

Document ID
1958813589149651291
Author
Greenberg C
Adams J
Mullen P
Koepke J
Publication year
Publication venue
American journal of clinical pathology

External Links

Snippet

The effect of calcium chloride (CaCl2) on the activated partial thromboplastin time (aPTT) of heparinized plasma was studied. The aPTT ratio (heparinized plasma: control plasma) increased as the CaCl2 concentration to recalcify the plasma was increased from 15 to 35 …
Continue reading at academic.oup.com (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/49—Blood
    • G01N33/4905—Determining clotting time of blood
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)
    • G01N2333/96441—Serine endopeptidases (3.4.21) with definite EC number
    • G01N2333/96461—Protein C (3.4.21.69)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/22—Haematology
    • G01N2800/226—Thrombotic disorders, i.e. thrombo-embolism irrespective of location/organ involved, e.g. renal vein thrombosis, venous thrombosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/745—Assays involving non-enzymic blood coagulation factors
    • G01N2333/75—Fibrin; Fibrinogen
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/22—Haematology
    • G01N2800/224—Haemostasis or coagulation

Similar Documents

Publication Publication Date Title
US20030064414A1 (en) Rapid assessment of coagulation activity in whole blood
Egeberg Inherited antithrombin deficiency causing thrombophilia
Favaloro et al. The new oral anticoagulants and the future of haemostasis laboratory testing
Yang et al. Prothrombin time
US5051357A (en) Method and assay using inactivation of factors Va and VIIIa by activated Protein C to diagnose thrombic disease or assay for Protein C and kit therefor
US9234902B2 (en) Method for monitoring anticoagulant therapy
JP5123496B2 (en) Methods for standardization of blood coagulation tests
Tiede et al. Acquired bleeding disorders
van den Bessekaar et al. Monitoring heparin therapy: relationships between the activated partial thromboplastin time and heparin assays based on ex-vivo heparin samples
CA2252983A1 (en) Method for determining the anticoagulatory potential of a sample
Blauhut et al. Activity of antithrombin III and effect of heparin on coagulation in shock
Reich et al. Comparison of bedside coagulation monitoring tests with standard laboratory tests in patients after cardiac surgery
Stief Inhibition of thrombin in plasma by heparin or arginine
EP1162457A2 (en) Multiple coagulation test system and method of using a multiple coagulation test system
Despotis et al. In Vitro reversal of Heparin Effect with Heparinas: evaluation with whole blood Prothrombin Time and activated partial Thromboplastin Time in Cardiac Surgical Patients
Greenberg et al. The effect of calcium ions on the activated partial thromboplastin time of heparinized plasma
Jankun et al. Experimental immunology Complex function of magnesium in blood clot formation and lysis
Kobayashi et al. Functional activity of protein S determined with use of protein C activated by venom activator.
Palmer Laboratory diagnosis of bleeding disorders: basic screening tests
Hoppensteadt et al. Factor X values as a means to assess the extent of oral anticoagulation in patients receiving antithrombin drugs
Walenga et al. In vitro coagulant and amidolytic methods for evaluating the activity of heparin and a low molecular weight derivative (PK 10169)
Hoppensteadt et al. Validity of serine protease inhibition tests in the evaluation and monitoring of the effect of heparin and its fractions
Smith et al. Factor IX metal ion-dependent antigen assays for measurement of warfarin effect
Brack et al. Prothrombin fragment F1+ 2 concentrations for monitoring anticoagulation therapy with heparin
Mason et al. Evolution and decay of platelet-agglutinating activity in normal and pathologic human plasmas